Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 55.77 percent decrease over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $9.043 million which missed the analyst consensus estimate of $16.170 million by 44.08 percent. This is a 79.47 percent decrease over sales of $44.056 million the same period last year.